Related Experiment Videos
Reduced-dose influenza vaccine.
Katleen N Wyatt1, Gina J Ryan, Kathleen A Sheerin
1Southern School of Pharmacy, Mercer University, Atlanta, GA 30341-4155, USA. ryan_gj@mercer.edu
The Annals of Pharmacotherapy
|July 13, 2006
Summary
Reduced-dose trivalent inactivated influenza vaccine showed similar immunogenicity to standard doses in healthy adults under 60. The Centers for Disease Control and Prevention does not recommend reduced-dose vaccines but prefers intramuscular administration if used during shortages.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Influenza poses a significant public health burden.
- Vaccination is a primary strategy for influenza prevention.
- Trivalent inactivated influenza vaccine (IIV3) is widely used.
Purpose of the Study:
- To assess the efficacy and safety of reduced-dose IIV3 in adults.
- To review current evidence on alternative dosing strategies for influenza vaccines.
Main Methods:
- A comprehensive literature search of MEDLINE (1966-May 2006) was performed.
- Key search terms included: inactivated, trivalent, influenza vaccine, dose, and intradermal.
- Four relevant studies were identified and analyzed.
Main Results:
- Reduced-dose IIV3 demonstrated comparable immunogenicity to standard doses in healthy adults younger than 60.
- Intramuscular vaccine administration resulted in fewer local adverse events compared to other routes.
- Variations in study designs and dosing limited direct comparisons.
Conclusions:
- The Centers for Disease Control and Prevention (CDC) currently advises against routine use of reduced-dose influenza vaccines.
- If reduced-dose vaccination is necessary due to vaccine shortages, it should be administered to healthy adults under 60.
- The intramuscular route is the preferred method for administration in such scenarios.